Overview Dividends

(EWTX) Edgewise Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US28036F1057

EDG-5506, EDG-7500, Oral, Small-Molecule, Muscular

Biotechnology
Market Cap in USD: 2,790m

IPO / Inception: 2021-03-26
Return 12m vs S&P 500: -22.2%

EPS (Earnings per Share)

EPS CAGR: -18.37%
EPS Trend: -60.8%

Last SUE: 0.28
Qual. Beats: 0

Revenue

Rev. CAGR: 0.00%
Rev. Trend: 20.2%

Last SUE: 0.00
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	77.5%
Value at Risk 5%th	106%
Relative Tail Risk	-16.82%

Reward TTM
Sharpe Ratio	0.23
Alpha	-31.81
CAGR/Max DD	0.56

Character TTM
Hurst Exponent	0.371
Beta	1.187
Beta Downside	1.940

Drawdowns 3y
Max DD	68.81%
Mean DD	30.76%
Median DD	28.92%

Description: EWTX Edgewise Therapeutics November 13, 2025

Edgewise Therapeutics (NASDAQ:EWTX) is a U.S. biotech focused on small-molecule therapies for genetically defined muscle disorders. Founded in 2017 and based in Boulder, Colorado, the firm’s core strategy is to target the underlying protein defects that cause conditions such as Duchenne and Becker muscular dystrophy.

Its lead candidate, **EDG-5506**, is an oral small molecule currently in Phase II trials aimed at restoring dystrophin function in dystrophinopathies. A second program, **EDG-7500**, targets hypertrophic cardiomyopathy and other severe cardiac diseases and is in Phase I. The pipeline also includes precision-medicine assets that modulate muscle-specific proteins, but none have entered clinical testing yet. *Assumption*: trial timelines will follow typical biotech averages (≈2 years from Phase II to potential NDA), but outcomes remain highly uncertain.

As of the latest 10-Q, Edgewise reported **≈$150 million in cash and equivalents**, giving it roughly a 12-month runway at current burn rates (≈$12 million / quarter). The biotech sector’s funding environment remains robust, with a 2024-2025 surge in venture capital for rare-disease therapeutics and a historical FDA approval rate of ~12 % for Phase II assets in muscular-dystrophy space-both factors that could materially affect valuation. *Uncertainty*: the company’s valuation is highly sensitive to Phase II readouts for EDG-5506, which could swing market cap by >30 %.

For a deeper, data-driven assessment of Edgewise’s risk-adjusted upside, consider exploring the analyst models and peer comparisons on **ValueRay**-the platform’s granular financial and clinical-trial dashboards can help you quantify the upside potential more precisely.

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-157.2m TTM) > 0 and > 6% of Revenue (6% = 127.1k TTM)

FCFTA -0.23 (>2.0%) and ΔFCFTA -1.20pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 26.1k% (prev 21.3k%; Δ 4739 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.23 (>3.0%) and CFO -132.2m > Net Income -157.2m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 26.51 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (105.5m) change vs 12m ago 12.45% (target <= -2.0% for YES)

Gross Margin -2.93% (prev -72.38%; Δ 69.45pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 0.39% (prev 0.44%; Δ -0.05pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -9.97 (EBITDA TTM -172.5m / Interest Expense TTM -17.5m) >= 6 (WARN >= 3)

Altman Z'' -19.67

(A) 0.95 = (Total Current Assets 573.9m - Total Current Liabilities 21.6m) / Total Assets 583.5m

(B) -0.85 = Retained Earnings (Balance) -496.2m / Total Assets 583.5m

(D) -19.96 = Book Value of Equity -495.4m / Total Liabilities 24.8m

Total Rating: -19.67 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 30.45

1. Piotroski 0.0pt

2. FCF Yield -5.95%

3. FCF Margin data missing

4. Debt/Equity 0.01

5. Debt/Ebitda 0.24

6. ROIC - WACC (= -44.70)%

7. RoE -30.88%

8. Rev. Trend 20.19%

9. EPS Trend -60.83%

What is the price of EWTX shares?

As of January 02, 2026, the stock is trading at USD 24.82 with a total of 1,093,873 shares traded.
Over the past week, the price has changed by -5.83%, over one month by -1.80%, over three months by +60.72% and over the past year by -8.19%.

Is EWTX a buy, sell or hold?

Edgewise Therapeutics has received a consensus analysts rating of 4.30. Therefore, it is recommended to buy EWTX.

Strong Buy: 5
Buy: 3
Hold: 2
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the EWTX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	38.2	53.8%
Analysts Target Price	38.2	53.8%
ValueRay Target Price	25.7	3.4%

EWTX Fundamental Data Overview December 28, 2025

Market Cap USD = 2.79b (2.79b USD * 1.0 USD.USD)
P/B = 4.9936
Beta = 0.268
Revenue TTM = 2.12m USD
EBIT TTM = -174.8m USD
EBITDA TTM = -172.5m USD
Long Term Debt = 4.18m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.01m USD (from shortTermDebt, last quarter)
Debt = 4.18m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -41.8m USD (from netDebt column, last quarter)
Enterprise Value = 2.23b USD (2.79b + Debt 4.18m - CCE 563.3m)
Interest Coverage Ratio = -9.97 (Ebit TTM -174.8m / Interest Expense TTM -17.5m)
FCF Yield = -5.95% (FCF TTM -132.6m / Enterprise Value 2.23b)
FCF Margin = -6262 % (FCF TTM -132.6m / Revenue TTM 2.12m)
Net Margin = -7424 % (Net Income TTM -157.2m / Revenue TTM 2.12m)
Gross Margin = -2.93% ((Revenue TTM 2.12m - Cost of Revenue TTM 2.18m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 3.82 (Enterprise Value 2.23b / Total Assets 583.5m)
Interest Expense / Debt = 74.31% (Interest Expense 3.11m / Debt 4.18m)
Taxrate = 0.00% (-1.0 / -133.8m)
NOPAT = -174.8m (EBIT -174.8m * (1 - 0.00%)) [loss with tax shield]
Current Ratio = 26.51 (Total Current Assets 573.9m / Total Current Liabilities 21.6m)
Debt / Equity = 0.01 (Debt 4.18m / totalStockholderEquity, last quarter 558.6m)
Debt / EBITDA = 0.24 (negative EBITDA) (Net Debt -41.8m / EBITDA -172.5m)
Debt / FCF = 0.32 (negative FCF - burning cash) (Net Debt -41.8m / FCF TTM -132.6m)
Total Stockholder Equity = 509.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -26.95% (Net Income -157.2m / Total Assets 583.5m)
RoE = -30.88% (Net Income TTM -157.2m / Total Stockholder Equity 509.2m)
RoCE = -34.05% (EBIT -174.8m / Capital Employed (Equity 509.2m + L.T.Debt 4.18m))
RoIC = -34.33% (negative operating profit) (NOPAT -174.8m / Invested Capital 509.2m)
WACC = 10.37% (E(2.79b)/V(2.79b) * Re(10.39%) + (debt cost/tax rate unavailable))
Discount Rate = 10.39% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 27.62%
Fair Price DCF = unknown (Cash Flow -132.6m)
EPS Correlation: -60.83 | EPS CAGR: -18.37% | SUE: 0.28 | # QB: 0
Revenue Correlation: 20.19 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.46 | Chg30d=+0.000 | Revisions Net=+2 | Analysts=6
EPS next Year (2026-12-31): EPS=-1.98 | Chg30d=+0.000 | Revisions Net=+2 | Growth EPS=-23.5% | Growth Revenue=+0.0%

Additional Sources for EWTX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle